Data intelligence platform TrialHub has partnered with EmVenio Research to bolster subject participation and expedite site selection for clinical trials.
Under the partnership, TrialHub will offer insights of patients on real-time basis and will aid EmVenio in carrying out an extensive range of trials of novel life-saving therapies.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
TrialHub Operations head Ralitsa Vaskova said: “We are delighted to welcome EmVenio on board and help their dedicated team of experts expand clinical trial access to underrepresented and underserved patient communities.”
Leveraging the data intelligence gathering platform of TrialHub, EmVenio can seamlessly locate the suitable markets to recruit trial subjects required to satisfy the participation targets of clinical research organisations and pharmaceutical sponsors.
Benchmarking and statistics from TrialHub will offer a comprehensive feasibility outline of the clinical research setting.
This approach aids EmVenio in efficiently choosing trial sites as per incidence of the disease, rates of enrolment and accessibility to healthcare providers and facilities that are readily available.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataEmVenio Research president Thad Wolfram said: “With TrialHub’s uniquely curated data, EmVenio can connect CROs and sponsors to the appropriate population of potential trial participants for a range of studies across a wide array of therapeutic areas.
“Faster and more intelligent access to data allows us to quickly identify and recommend the best communities in which to conduct a trial and activate it in a more efficient manner, saving our clients time and money and providing them the results they need sooner than later.”
